GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » Net Margin %

Infant Bacterial Therapeutics AB (STU:9IB) Net Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Infant Bacterial Therapeutics AB's Net Income for the three months ended in Dec. 2024 was €-2.94 Mil. Infant Bacterial Therapeutics AB's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, Infant Bacterial Therapeutics AB's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Infant Bacterial Therapeutics AB's Net Margin % or its related term are showing as below:


STU:9IB's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -120.87
* Ranked among companies with meaningful Net Margin % only.

Infant Bacterial Therapeutics AB Net Margin % Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Net Margin % Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Infant Bacterial Therapeutics AB's Net Margin %

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Net Margin % falls into.


;
;

Infant Bacterial Therapeutics AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Infant Bacterial Therapeutics AB's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-11.902/0
= %

Infant Bacterial Therapeutics AB's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-2.935/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infant Bacterial Therapeutics AB  (STU:9IB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Infant Bacterial Therapeutics AB Net Margin % Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines